Search

More than half of the global population is unable to consume dairy products due to lactose intolerance (hypolactasia). Current enzyme replacement therapy methods are insufficiently effective as a therapeutic approach to treating lactose intolerance. The encapsulation of β-galactosidase in polyelectrolyte microcapsules by using the layer-by-layer method could be a possible solution to this problem. In this study, adsorption and co-precipitation methods were employed for encapsulating β-galactosidase in polyelectrolyte microcapsules composed of (polyallylamine /polystyrene sulphonate)₃. As a result, the co-precipitation method was chosen for β-galactosidase encapsulation. The adsorption method permits to encapsulate six times less enzyme compared with the co-precipitation method; the β-galactosidase encapsulated via the co-precipitation method released no more than 20% of the initially encapsulated enzyme in pH 2 or 1 M NaCl solutions. In contrast, when using the sorption method, about 100% of the initially encapsulated enzyme was released from the microcapsules under the conditions described above. The co-precipitation method effectively prevents the complete loss of enzyme activity after 2 h of incubation in a solution with pH 2 while also alleviating the adverse effects of ionic strength. Consequently, the encapsulated form of β-galactosidase shows promise as a potential therapeutic agent for enzyme replacement therapy in the treatment of hypolactasia. [ABSTRACT FROM AUTHOR]

One of the key physicochemical parameters of polyelectrolyte microcapsules (PMCs) is their buffer capacity (BC). The BC of the microcapsules allows for an assessment of the change in protonation state across the entire polyelectrolyte system, which directly impacts the buffer barrier of PMCs, as well as the stability and physical properties of their shell. However, the buffer capacity of PMCs and their behavior under changes in ionic strength and temperature can differ depending on the type of core used to form the microcapsules. As part of this study, we revealed the buffer capacity (BC) of polyelectrolyte microcapsules formed on polystyrene cores (PMCPs) and studied the influence of ionic strength and environmental temperature on the BC of these capsules. We found that the buffer capacity of PMCPs differs from the BC of water at a pH above 8; the addition of sodium chloride leads to an increase in buffer capacity in alkaline conditions, and conversely, thermal treatment leads to its decrease at a pH of 9. The results obtained are different from the BC of polyelectrolyte microcapsules formed on CaCO3 cores, which suggests a difference in the physicochemical properties of these types of capsules. The buffer capacity of polyelectrolyte microcapsules depends on the type of template used. [ABSTRACT FROM AUTHOR]

Allapinin has antiarrhythmic activity and can be used to prevent and treat various supraventricular and ventricular arrhythmias. Nevertheless, it is highly toxic and has a number of side effects associated with non-specific accumulation in various tissues. The complex of this substance with the monoammonium salt of glycyrrhizic acid (Al:MASGA) has less toxicity and improved antiarrhythmic activity. However, the encapsulation of Al:MASGA in polyelectrolyte microcapsules (PMC) for prolonged release will reduce the residual adverse effects of this drug. In this work, the possibility of encapsulating the allapinin–MASGA complex in polyelectrolyte microcapsules based on polyallylamine and polystyrene sulfonate was investigated. The encapsulation methods of the allapinin–MASGA in polyelectrolyte microcapsules by adsorption and coprecipitation were compared. It was found that the coprecipitation method did not result in the encapsulation of Al:MASGA. The sorption method facilitated the encapsulation of up to 80% of the original substance content in solution in PMC. The release of the encapsulated substance was further investigated, and it was shown that the release of the encapsulated Al:MASGA was independent of the substance content in the capsules, but at pH 5, a two-fold decrease in the rate of drug release was observed. [ABSTRACT FROM AUTHOR]

Using fluorescent spectroscopy, we examined degradation of PAH/PSS microcapsule shells and release of a protein from them. The processes were controlled by various concentrations of NaCl and (NH4)2SO4 and levels of pH: 5 and 7.4. We found that a high concentration of sodium chloride (2 М) causes essential dissociation of PAH from the upper shell layer and explained this by the layer loosening under the ionic strength. Using the optical spectroscopy, we determined amount of a microcapsule polyelectrolyte (PAH) and found that less than 20% of it can be released into 2М NaCl solution, and only 2% can be released into the water medium. Increase in solution pH up to 7.4 causes peeling of PAH too, however, temperature increase up to 37°С decreases this effect due to the structuring and compacting of the shell demonstrated by electron-microscopic studies. And finally we found that a scarce release of an encapsulated protein from the microcapsules does not depend on the presence of salts in the medium, their concentrations and a medium pH. [ABSTRACT FROM AUTHOR]

One of the prerequisites of successful address delivery is controlling the release of encapsulated drugs. The new method of bacterial spore encapsulation in polyelectrolyte microcapsules allows for degrading the nanoscale membrane shell of microcapsules. The possibility of encapsulating spore forms of Bacillus subtilis in polystyrenesulfonate sodium/ polyallylamine hydrochloride (PSS/PAH) polyelectrolyte microcapsules was demonstrated. The activation and growth on a nutrient medium of encapsulated bacterial spores led to 60% degradation of the microcapsules nanoscale membrane shell. As a result, 18.5% of Fluorescein isothiocyanatedextran was encapsulated into polyelectrolyte microcapsules, and 28.6% of the encapsulated concentration of FITC-dextran was released into the solution. [ABSTRACT FROM AUTHOR]

The degradation of polyelectrolyte microcapsules formed on protein-free CaCO 3 particles consisting of polyallylamine (PAH) and polystyrene sulfonate (PSS) and the resulting yield of protein in the presence of various salts of different concentrations, as well as at two pH values, was studied by fluorescence spectroscopy; the protein was incorporated into prepared microcapsules by adsorption. It was found that a high concentration of sodium chloride (2 M) leads to considerable dissociation of PAH, which is apparently due to the loosening of polyelectrolytes under the action of ionic strength. At the same time, 0.2 M sodium chloride and ammonium sulfate of the same ionic strength (0.1 M) exert less influence on the amount of dissociated polymer. In the case of ammonium sulfate (0.1 M), the effect is due to the competitive binding of sulfate anions to the amino groups of the polyelectrolyte. However, unlike microcapsules formed on CaCO 3 particles containing protein, the dissociation of polyelectrolyte from microcapsules formed on protein-free particles increased with increasing temperature. Apparently, a similar effect is associated with the absence of a distinct shell, which was observed on microcapsules formed on protein-containing CaCO 3 particles. The high level of the presence of Fluorescein isothiocyanate (FITC)-labeled Bovine Serum Albumin (BSA) in the supernatant is explained by the large amount of electrostatically bound protein and the absence of a shell that prevents the release of the protein from the microcapsules. In 2M NaCl, during the observation period, the amount of the released protein did not exceed 70% of the total protein content in the capsules, in control samples, this value does not exceed 8%, which indicates the predominantly electrostatic nature of protein retention in capsules formed on protein-free CaCO 3 particles. The increase in protein yield and peeling of PAH with increasing pH is explained by the proximity of pH 7 to the point of charge exchange of the amino group of polyelectrolyte, as a result of the dissociation of the microcapsule., Competing Interests: The authors declare no conflicts of interest.